266 related articles for article (PubMed ID: 22449547)
61. Non-steroidal antiandrogens: synthesis and biological profile of high-affinity ligands for the androgen receptor.
Teutsch G; Goubet F; Battmann T; Bonfils A; Bouchoux F; Cerede E; Gofflo D; Gaillard-Kelly M; Philibert D
J Steroid Biochem Mol Biol; 1994 Jan; 48(1):111-9. PubMed ID: 8136296
[TBL] [Abstract][Full Text] [Related]
62. Anti-androgen receptor signaling and prostate cancer inhibitory effects of sucrose- and benzophenone-compounds.
Wang Z; Lee HJ; Wang L; Jiang C; Baek NI; Kim SH; Lü J
Pharm Res; 2009 May; 26(5):1140-8. PubMed ID: 19266268
[TBL] [Abstract][Full Text] [Related]
63. Identification and characterization of MEL-3, a novel AR antagonist that suppresses prostate cancer cell growth.
Helsen C; Marchand A; Chaltin P; Munck S; Voet A; Verstuyf A; Claessens F
Mol Cancer Ther; 2012 Jun; 11(6):1257-68. PubMed ID: 22496481
[TBL] [Abstract][Full Text] [Related]
64. 7-Substituted umbelliferone derivatives as androgen receptor antagonists for the potential treatment of prostate and breast cancer.
Kandil S; Westwell AD; McGuigan C
Bioorg Med Chem Lett; 2016 Apr; 26(8):2000-4. PubMed ID: 26965862
[TBL] [Abstract][Full Text] [Related]
65. Design, synthesis and biological evaluation of novel 3-oxo-4-oxa-5α-androst-17β-amide derivatives as dual 5α-reductase inhibitors and androgen receptor antagonists.
Lao K; Sun J; Wang C; Wang Y; You Q; Xiao H; Xiang H
Bioorg Med Chem Lett; 2017 Sep; 27(17):4212-4217. PubMed ID: 28757062
[TBL] [Abstract][Full Text] [Related]
66. Secreted indicators of androgen receptor activity in breast cancer pre-clinical models.
Hanamura T; Christenson JL; O'Neill KI; Rosas E; Spoelstra NS; Williams MM; Richer JK
Breast Cancer Res; 2021 Nov; 23(1):102. PubMed ID: 34736512
[TBL] [Abstract][Full Text] [Related]
67. A selective androgen receptor modulator with minimal prostate hypertrophic activity restores lean body mass in aged orchidectomized male rats.
Allan G; Sbriscia T; Linton O; Lai MT; Haynes-Johnson D; Bhattacharjee S; Ng R; Sui Z; Lundeen S
J Steroid Biochem Mol Biol; 2008 Jun; 110(3-5):207-13. PubMed ID: 18502117
[TBL] [Abstract][Full Text] [Related]
68. In silico and in vitro assessment of androgen receptor antagonists.
Serçinoğlu O; Bereketoglu C; Olsson PE; Pradhan A
Comput Biol Chem; 2021 Jun; 92():107490. PubMed ID: 33932781
[TBL] [Abstract][Full Text] [Related]
69. Structure-activity relationship of novel (benzoylaminophenoxy)phenol derivatives as anti-prostate cancer agents.
Kazui Y; Fujii S; Yamada A; Ishigami-Yuasa M; Kagechika H; Tanatani A
Bioorg Med Chem; 2018 Oct; 26(18):5118-5127. PubMed ID: 30228001
[TBL] [Abstract][Full Text] [Related]
70. In silico discovery of androgen receptor antagonists with activity in castration resistant prostate cancer.
Shen HC; Shanmugasundaram K; Simon NI; Cai C; Wang H; Chen S; Balk SP; Rigby AC
Mol Endocrinol; 2012 Nov; 26(11):1836-46. PubMed ID: 23023563
[TBL] [Abstract][Full Text] [Related]
71. Modeling androgen receptor flexibility: a binding mode hypothesis of CYP17 inhibitors/antiandrogens for prostate cancer therapy.
Gianti E; Zauhar RJ
J Chem Inf Model; 2012 Oct; 52(10):2670-83. PubMed ID: 22924551
[TBL] [Abstract][Full Text] [Related]
72. Influence of the substitution of 11-methylene, delta(15), and/or 18-methyl groups in norethisterone on receptor binding, transactivation assays and biological activities in animals.
Deckers GH; Schoonen WG; Kloosterboer HJ
J Steroid Biochem Mol Biol; 2000 Oct; 74(3):83-92. PubMed ID: 11086227
[TBL] [Abstract][Full Text] [Related]
73. The effect of androgens and antiandrogens on the immunohistochemical localization of the androgen receptor in accessory reproductive organs of male rats.
Paris F; Weinbauer GF; Blüm V; Nieschlag E
J Steroid Biochem Mol Biol; 1994 Jan; 48(1):129-37. PubMed ID: 8136298
[TBL] [Abstract][Full Text] [Related]
74. Effects of new 17alpha-hydroxylase/C(17,20)-lyase inhibitors on LNCaP prostate cancer cell growth in vitro and in vivo.
Grigoryev DN; Long BJ; Nnane IP; Njar VC; Liu Y; Brodie AM
Br J Cancer; 1999 Oct; 81(4):622-30. PubMed ID: 10574247
[TBL] [Abstract][Full Text] [Related]
75. Action of prolactin in regressing prostate: independent of action mediated by androgen receptors.
Assimos D; Smith C; Lee C; Grayhack JT
Prostate; 1984; 5(6):589-95. PubMed ID: 6494057
[TBL] [Abstract][Full Text] [Related]
76. 7alpha-methyl-19-nortestosterone, a synthetic androgen with high potency: structure-activity comparisons with other androgens.
Kumar N; Crozat A; Li F; Catterall JF; Bardin CW; Sundaram K
J Steroid Biochem Mol Biol; 1999 Dec; 71(5-6):213-22. PubMed ID: 10704910
[TBL] [Abstract][Full Text] [Related]
77. The role of microRNAs 371 and 34a in androgen receptor control influencing prostate cancer behavior.
Leite KR; Morais DR; Florez MG; Reis ST; Iscaife A; Viana N; Moura CM; Silva IA; Katz BS; Pontes J; Nesrallah A; Srougi M
Urol Oncol; 2015 Jun; 33(6):267.e15-22. PubMed ID: 25920548
[TBL] [Abstract][Full Text] [Related]
78. A comparative study of the selectivity and efficiency of target tissue uptake of five tritium-labeled androgens in the rat.
Carlson KE; Katzenellenbogen JA
J Steroid Biochem; 1990 Aug; 36(6):549-61. PubMed ID: 2214772
[TBL] [Abstract][Full Text] [Related]
79. Discovery of novel androgen receptor antagonists: a hybrid approach of pharmacophore-based and docking-based virtual screening.
Liu J; Liu B; Guo G; Jing Y; Zhao G
Anticancer Drugs; 2015 Aug; 26(7):747-53. PubMed ID: 25933245
[TBL] [Abstract][Full Text] [Related]
80. In vitro and in vivo effects of 17beta-trenbolone: a feedlot effluent contaminant.
Wilson VS; Lambright C; Ostby J; Gray LE
Toxicol Sci; 2002 Dec; 70(2):202-11. PubMed ID: 12441365
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
